Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study
Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resec...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yamaguchi, Toshifumi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 26(2023), 2 vom: 25. Jan., Seite 307-316 |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2023 ; number:2 ; day:25 ; month:01 ; pages:307-316 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-023-01363-8 |
|---|
| Katalog-ID: |
SPR049446142 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049446142 | ||
| 003 | DE-627 | ||
| 005 | 20240125064747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-023-01363-8 |2 doi | |
| 035 | |a (DE-627)SPR049446142 | ||
| 035 | |a (SPR)s10120-023-01363-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamaguchi, Toshifumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. | ||
| 650 | 4 | |a S-1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gastirc cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oligo metastasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Liver metastasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Post-operative chemotherapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Takashima, Atsuo |0 (orcid)0000-0002-8456-1248 |4 aut | |
| 700 | 1 | |a Nagashima, Kengo |4 aut | |
| 700 | 1 | |a Kumagai, Koshi |4 aut | |
| 700 | 1 | |a Yamada, Tatsuya |4 aut | |
| 700 | 1 | |a Terashima, Masanori |4 aut | |
| 700 | 1 | |a Yabusaki, Hiroshi |4 aut | |
| 700 | 1 | |a Nishikawa, Kazuhiro |4 aut | |
| 700 | 1 | |a Tanabe, Kazuaki |4 aut | |
| 700 | 1 | |a Yunome, Gen |4 aut | |
| 700 | 1 | |a Kawachi, Yasuyuki |4 aut | |
| 700 | 1 | |a Yamada, Takanobu |4 aut | |
| 700 | 1 | |a Fukagawa, Takeo |4 aut | |
| 700 | 1 | |a Kinoshita, Takahiro |4 aut | |
| 700 | 1 | |a Watanabe, Masaya |4 aut | |
| 700 | 1 | |a Ishiyama, Koshiro |4 aut | |
| 700 | 1 | |a Inoue, Kentaro |4 aut | |
| 700 | 1 | |a Boku, Narikazu |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 26(2023), 2 vom: 25. Jan., Seite 307-316 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:2 |g day:25 |g month:01 |g pages:307-316 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-023-01363-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 2 |b 25 |c 01 |h 307-316 | ||
| author_variant |
t y ty a t at k n kn k k kk t y ty m t mt h y hy k n kn k t kt g y gy y k yk t y ty t f tf t k tk m w mw k i ki k i ki n b nb |
|---|---|
| matchkey_str |
yamaguchitoshifumitakashimaatsuonagashim:2023----:vlaighefccopsoeaiehmteayfecrtvrscinftgigsrcacrihycrnuoioe |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1007/s10120-023-01363-8 doi (DE-627)SPR049446142 (SPR)s10120-023-01363-8-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. S-1 (dpeaa)DE-He213 Gastirc cancer (dpeaa)DE-He213 Oligo metastasis (dpeaa)DE-He213 Liver metastasis (dpeaa)DE-He213 Post-operative chemotherapy (dpeaa)DE-He213 Takashima, Atsuo (orcid)0000-0002-8456-1248 aut Nagashima, Kengo aut Kumagai, Koshi aut Yamada, Tatsuya aut Terashima, Masanori aut Yabusaki, Hiroshi aut Nishikawa, Kazuhiro aut Tanabe, Kazuaki aut Yunome, Gen aut Kawachi, Yasuyuki aut Yamada, Takanobu aut Fukagawa, Takeo aut Kinoshita, Takahiro aut Watanabe, Masaya aut Ishiyama, Koshiro aut Inoue, Kentaro aut Boku, Narikazu aut Enthalten in Gastric Cancer Springer-Verlag, 2002 26(2023), 2 vom: 25. Jan., Seite 307-316 (DE-627)SPR009286586 nnns volume:26 year:2023 number:2 day:25 month:01 pages:307-316 https://dx.doi.org/10.1007/s10120-023-01363-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 26 2023 2 25 01 307-316 |
| spelling |
10.1007/s10120-023-01363-8 doi (DE-627)SPR049446142 (SPR)s10120-023-01363-8-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. S-1 (dpeaa)DE-He213 Gastirc cancer (dpeaa)DE-He213 Oligo metastasis (dpeaa)DE-He213 Liver metastasis (dpeaa)DE-He213 Post-operative chemotherapy (dpeaa)DE-He213 Takashima, Atsuo (orcid)0000-0002-8456-1248 aut Nagashima, Kengo aut Kumagai, Koshi aut Yamada, Tatsuya aut Terashima, Masanori aut Yabusaki, Hiroshi aut Nishikawa, Kazuhiro aut Tanabe, Kazuaki aut Yunome, Gen aut Kawachi, Yasuyuki aut Yamada, Takanobu aut Fukagawa, Takeo aut Kinoshita, Takahiro aut Watanabe, Masaya aut Ishiyama, Koshiro aut Inoue, Kentaro aut Boku, Narikazu aut Enthalten in Gastric Cancer Springer-Verlag, 2002 26(2023), 2 vom: 25. Jan., Seite 307-316 (DE-627)SPR009286586 nnns volume:26 year:2023 number:2 day:25 month:01 pages:307-316 https://dx.doi.org/10.1007/s10120-023-01363-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 26 2023 2 25 01 307-316 |
| allfields_unstemmed |
10.1007/s10120-023-01363-8 doi (DE-627)SPR049446142 (SPR)s10120-023-01363-8-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. S-1 (dpeaa)DE-He213 Gastirc cancer (dpeaa)DE-He213 Oligo metastasis (dpeaa)DE-He213 Liver metastasis (dpeaa)DE-He213 Post-operative chemotherapy (dpeaa)DE-He213 Takashima, Atsuo (orcid)0000-0002-8456-1248 aut Nagashima, Kengo aut Kumagai, Koshi aut Yamada, Tatsuya aut Terashima, Masanori aut Yabusaki, Hiroshi aut Nishikawa, Kazuhiro aut Tanabe, Kazuaki aut Yunome, Gen aut Kawachi, Yasuyuki aut Yamada, Takanobu aut Fukagawa, Takeo aut Kinoshita, Takahiro aut Watanabe, Masaya aut Ishiyama, Koshiro aut Inoue, Kentaro aut Boku, Narikazu aut Enthalten in Gastric Cancer Springer-Verlag, 2002 26(2023), 2 vom: 25. Jan., Seite 307-316 (DE-627)SPR009286586 nnns volume:26 year:2023 number:2 day:25 month:01 pages:307-316 https://dx.doi.org/10.1007/s10120-023-01363-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 26 2023 2 25 01 307-316 |
| allfieldsGer |
10.1007/s10120-023-01363-8 doi (DE-627)SPR049446142 (SPR)s10120-023-01363-8-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. S-1 (dpeaa)DE-He213 Gastirc cancer (dpeaa)DE-He213 Oligo metastasis (dpeaa)DE-He213 Liver metastasis (dpeaa)DE-He213 Post-operative chemotherapy (dpeaa)DE-He213 Takashima, Atsuo (orcid)0000-0002-8456-1248 aut Nagashima, Kengo aut Kumagai, Koshi aut Yamada, Tatsuya aut Terashima, Masanori aut Yabusaki, Hiroshi aut Nishikawa, Kazuhiro aut Tanabe, Kazuaki aut Yunome, Gen aut Kawachi, Yasuyuki aut Yamada, Takanobu aut Fukagawa, Takeo aut Kinoshita, Takahiro aut Watanabe, Masaya aut Ishiyama, Koshiro aut Inoue, Kentaro aut Boku, Narikazu aut Enthalten in Gastric Cancer Springer-Verlag, 2002 26(2023), 2 vom: 25. Jan., Seite 307-316 (DE-627)SPR009286586 nnns volume:26 year:2023 number:2 day:25 month:01 pages:307-316 https://dx.doi.org/10.1007/s10120-023-01363-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 26 2023 2 25 01 307-316 |
| allfieldsSound |
10.1007/s10120-023-01363-8 doi (DE-627)SPR049446142 (SPR)s10120-023-01363-8-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. S-1 (dpeaa)DE-He213 Gastirc cancer (dpeaa)DE-He213 Oligo metastasis (dpeaa)DE-He213 Liver metastasis (dpeaa)DE-He213 Post-operative chemotherapy (dpeaa)DE-He213 Takashima, Atsuo (orcid)0000-0002-8456-1248 aut Nagashima, Kengo aut Kumagai, Koshi aut Yamada, Tatsuya aut Terashima, Masanori aut Yabusaki, Hiroshi aut Nishikawa, Kazuhiro aut Tanabe, Kazuaki aut Yunome, Gen aut Kawachi, Yasuyuki aut Yamada, Takanobu aut Fukagawa, Takeo aut Kinoshita, Takahiro aut Watanabe, Masaya aut Ishiyama, Koshiro aut Inoue, Kentaro aut Boku, Narikazu aut Enthalten in Gastric Cancer Springer-Verlag, 2002 26(2023), 2 vom: 25. Jan., Seite 307-316 (DE-627)SPR009286586 nnns volume:26 year:2023 number:2 day:25 month:01 pages:307-316 https://dx.doi.org/10.1007/s10120-023-01363-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 26 2023 2 25 01 307-316 |
| language |
English |
| source |
Enthalten in Gastric Cancer 26(2023), 2 vom: 25. Jan., Seite 307-316 volume:26 year:2023 number:2 day:25 month:01 pages:307-316 |
| sourceStr |
Enthalten in Gastric Cancer 26(2023), 2 vom: 25. Jan., Seite 307-316 volume:26 year:2023 number:2 day:25 month:01 pages:307-316 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
S-1 Gastirc cancer Oligo metastasis Liver metastasis Post-operative chemotherapy |
| isfreeaccess_bool |
false |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Yamaguchi, Toshifumi @@aut@@ Takashima, Atsuo @@aut@@ Nagashima, Kengo @@aut@@ Kumagai, Koshi @@aut@@ Yamada, Tatsuya @@aut@@ Terashima, Masanori @@aut@@ Yabusaki, Hiroshi @@aut@@ Nishikawa, Kazuhiro @@aut@@ Tanabe, Kazuaki @@aut@@ Yunome, Gen @@aut@@ Kawachi, Yasuyuki @@aut@@ Yamada, Takanobu @@aut@@ Fukagawa, Takeo @@aut@@ Kinoshita, Takahiro @@aut@@ Watanabe, Masaya @@aut@@ Ishiyama, Koshiro @@aut@@ Inoue, Kentaro @@aut@@ Boku, Narikazu @@aut@@ |
| publishDateDaySort_date |
2023-01-25T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR049446142 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR049446142</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240125064747.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-023-01363-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049446142</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-023-01363-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yamaguchi, Toshifumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">S-1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastirc cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligo metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liver metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Post-operative chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takashima, Atsuo</subfield><subfield code="0">(orcid)0000-0002-8456-1248</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagashima, Kengo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumagai, Koshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Tatsuya</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terashima, Masanori</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yabusaki, Hiroshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishikawa, Kazuhiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanabe, Kazuaki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yunome, Gen</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawachi, Yasuyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Takanobu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fukagawa, Takeo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kinoshita, Takahiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Watanabe, Masaya</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishiyama, Koshiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Inoue, Kentaro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boku, Narikazu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">26(2023), 2 vom: 25. Jan., Seite 307-316</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">day:25</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:307-316</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-023-01363-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="b">25</subfield><subfield code="c">01</subfield><subfield code="h">307-316</subfield></datafield></record></collection>
|
| author |
Yamaguchi, Toshifumi |
| spellingShingle |
Yamaguchi, Toshifumi misc S-1 misc Gastirc cancer misc Oligo metastasis misc Liver metastasis misc Post-operative chemotherapy Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| authorStr |
Yamaguchi, Toshifumi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study S-1 (dpeaa)DE-He213 Gastirc cancer (dpeaa)DE-He213 Oligo metastasis (dpeaa)DE-He213 Liver metastasis (dpeaa)DE-He213 Post-operative chemotherapy (dpeaa)DE-He213 |
| topic |
misc S-1 misc Gastirc cancer misc Oligo metastasis misc Liver metastasis misc Post-operative chemotherapy |
| topic_unstemmed |
misc S-1 misc Gastirc cancer misc Oligo metastasis misc Liver metastasis misc Post-operative chemotherapy |
| topic_browse |
misc S-1 misc Gastirc cancer misc Oligo metastasis misc Liver metastasis misc Post-operative chemotherapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| ctrlnum |
(DE-627)SPR049446142 (SPR)s10120-023-01363-8-e |
| title_full |
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| author_sort |
Yamaguchi, Toshifumi |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
307 |
| author_browse |
Yamaguchi, Toshifumi Takashima, Atsuo Nagashima, Kengo Kumagai, Koshi Yamada, Tatsuya Terashima, Masanori Yabusaki, Hiroshi Nishikawa, Kazuhiro Tanabe, Kazuaki Yunome, Gen Kawachi, Yasuyuki Yamada, Takanobu Fukagawa, Takeo Kinoshita, Takahiro Watanabe, Masaya Ishiyama, Koshiro Inoue, Kentaro Boku, Narikazu |
| container_volume |
26 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yamaguchi, Toshifumi |
| doi_str_mv |
10.1007/s10120-023-01363-8 |
| normlink |
(ORCID)0000-0002-8456-1248 |
| normlink_prefix_str_mv |
(orcid)0000-0002-8456-1248 |
| title_sort |
evaluating the efficacy of post-operative chemotherapy after curative resection of stage iv gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| title_auth |
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| abstract |
Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstractGer |
Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstract_unstemmed |
Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival. © The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
2 |
| title_short |
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study |
| url |
https://dx.doi.org/10.1007/s10120-023-01363-8 |
| remote_bool |
true |
| author2 |
Takashima, Atsuo Nagashima, Kengo Kumagai, Koshi Yamada, Tatsuya Terashima, Masanori Yabusaki, Hiroshi Nishikawa, Kazuhiro Tanabe, Kazuaki Yunome, Gen Kawachi, Yasuyuki Yamada, Takanobu Fukagawa, Takeo Kinoshita, Takahiro Watanabe, Masaya Ishiyama, Koshiro Inoue, Kentaro Boku, Narikazu |
| author2Str |
Takashima, Atsuo Nagashima, Kengo Kumagai, Koshi Yamada, Tatsuya Terashima, Masanori Yabusaki, Hiroshi Nishikawa, Kazuhiro Tanabe, Kazuaki Yunome, Gen Kawachi, Yasuyuki Yamada, Takanobu Fukagawa, Takeo Kinoshita, Takahiro Watanabe, Masaya Ishiyama, Koshiro Inoue, Kentaro Boku, Narikazu |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-023-01363-8 |
| up_date |
2024-07-04T00:50:39.975Z |
| _version_ |
1803607594737074176 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR049446142</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240125064747.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-023-01363-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049446142</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-023-01363-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yamaguchi, Toshifumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Surgical resection of oligo-metastasis in gastric cancer (GC) is weakly recommended for patients without other incurable factors in the Japanese GC Treatment Guidelines. While post-operative chemotherapy is the standard treatment in patients with stage II or III GC, its efficacy for resected stage IV GC is unclear. This study aimed to evaluate the efficacy of post-operative chemotherapy after curative resection of GC with oligo-metastasis. Methods We retrospectively reviewed the medical records of patients with GC who were diagnosed with synchronous oligo-metastasis at 20 institutions in Japan between 2007 and 2012. The selection criteria were: adenocarcinoma, stage IV with oligo-metastasis at liver or lymph node without other distant metastasis, curative resection including synchronous oligo-metastasis, and no prior treatment of GC before surgery. Results A total of 110 patients were collected. Of the 94 eligible patients, 84 underwent gastrectomy with surgical resection of oligo-metastasis (39 [41%] liver metastasis and 55, [59%] distant lymph node metastasis), followed by post-operative chemotherapy with S-1 (S1: n = 55), S1 plus cisplatin (CS: n = 22), or Others (n = 7). Moreover, 10 patients did not receive post-operative chemotherapy (Non-Cx). The median overall survival (OS) was 35.2 and 11.1 months in the post-operative chemotherapy and Non-Cx groups (hazard ratio, 3.56; 95% confidence interval, 1.74–7.30; p < 0.001), respectively. In multivariable analysis, Non-Cx and age over 70 years were identified as poor prognostic factors for OS (p < 0.05). Conclusions Curative resection followed by post-operative chemotherapy in patients with GC with synchronous oligo-metastasis showed favorable survival.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">S-1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastirc cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligo metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liver metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Post-operative chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takashima, Atsuo</subfield><subfield code="0">(orcid)0000-0002-8456-1248</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagashima, Kengo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumagai, Koshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Tatsuya</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terashima, Masanori</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yabusaki, Hiroshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishikawa, Kazuhiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanabe, Kazuaki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yunome, Gen</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawachi, Yasuyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Takanobu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fukagawa, Takeo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kinoshita, Takahiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Watanabe, Masaya</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishiyama, Koshiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Inoue, Kentaro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boku, Narikazu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">26(2023), 2 vom: 25. Jan., Seite 307-316</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">day:25</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:307-316</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-023-01363-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="b">25</subfield><subfield code="c">01</subfield><subfield code="h">307-316</subfield></datafield></record></collection>
|
| score |
7.402767 |